Related Experiment Videos
Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated
C Campagnoli1, N Biglia, M G Lanza
1Department of Endocrinologic Gynaecology, St. Anna Hospital, Turin, Italy.
Maturitas
|May 1, 1994
Summary
Oral estrogen therapy decreases insulin-like growth factor I (IGF-I) and increases sex hormone binding globulin (SHBG). Androgenic progestogens like NETA may counteract these effects, potentially impacting breast cancer risk.
Area of Science:
- Endocrinology
- Reproductive Medicine
- Oncology
Background:
- Postmenopausal hormone therapy.
- Estrogen's effect on insulin-like growth factor I (IGF-I) and sex hormone binding globulin (SHBG).
- Potential influence of progestogens on these effects.
Purpose of the Study:
- To investigate if androgenic progestogens oppose the effects of oral estrogens on serum IGF-I and SHBG.
- To compare the effects of different progestogens (dydrogesterone and norethisterone acetate) when added to oral conjugated estrogens or transdermal estradiol.
Main Methods:
- Two groups of postmenopausal women received oral conjugated estrogens (oCE) or transdermal estradiol (tdE2).
- Treatment phases involved adding dydrogesterone (DYDR) followed by norethisterone acetate (NETA).
- Serum levels of IGF-I and SHBG were measured at each phase.
Main Results:
- Oral conjugated estrogens with dydrogesterone increased SHBG and decreased IGF-I.
- Adding norethisterone acetate reversed these effects, returning IGF-I to baseline.
- Transdermal estradiol showed no initial changes, but adding NETA decreased SHBG and slightly increased IGF-I.
Conclusions:
- Differential effects of oral vs. transdermal estrogen, and progestogen type, on IGF-I and SHBG were observed.
- These hormonal shifts may have implications for breast cancer risk assessment.
- Further research is warranted to elucidate the clinical significance of these findings.